Výsledky vyhledávání - "Tetsuro, Otsuka"

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat

Autor: Tadao, Akizawa, Keiko, Tanaka-Amino, Tetsuro, Otsuka, Yusuke, Yamaguchi

Publikováno v: Clinical and Experimental Nephrology. 26:843-850

Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in patients with non-dia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d55e5ead40ff34216ec69e2d9fb129
https://doi.org/10.1007/s10157-022-02225-w

Zobrazit plný text záznamu

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin

Autor: Yasir J. Sepah, Quan Dong Nguyen, Yusuke Yamaguchi, Tetsuro Otsuka, Yoshikatsu Majikawa, Michael Reusch, Tadao Akizawa

Publikováno v: Kidney International Reports. 7:763-775

Roxadustat is an orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that represents a novel therapeutic option for patients with anemia of chronic kidney disease (CKD).Conducted in Japan, CL-0307 (NCT02952092) and CL-310

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c3866faa9be592f927f528d9186281
https://doi.org/10.1016/j.ekir.2022.01.1045

Zobrazit plný text záznamu

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD

Autor: Yusuke Yamaguchi, Manabu Iwasaki, Tadao Akizawa, Michael Reusch, Tetsuro Otsuka

Publikováno v: Kidney International Reports

Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (ND

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a861e6689271ef9dcda7394262c63ba
https://doi.org/10.1016/j.ekir.2021.04.003

Zobrazit plný text záznamu

Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients

Autor: Yusuke Yamaguchi, Tadao Akizawa, Keiko Tanaka-Amino, Tetsuro Otsuka

Publikováno v: Am J Nephrol

Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-depend

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::797dc94288379336b25d27f491306f2b
https://europepmc.org/articles/PMC8686708/

Zobrazit plný text záznamu

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study

Autor: Michael Reusch, Tetsuro Otsuka, Tadao Akizawa, Mai Ueno

Publikováno v: Therapeutic Apheresis and Dialysis

Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24‐week study investigated the efficacy and safety of roxadust

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a41998b3dc7cd6a0577e57ab67780000
https://doi.org/10.1111/1744-9987.12888

Zobrazit plný text záznamu

A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis

Autor: Yusuke Yamaguchi, Michael Reusch, Tadao Akizawa, Tetsuro Otsuka

Publikováno v: Nephron Clin Pract

Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia in Japan for patients with dialysis-dependent (DD) chronic kidney disease (CKD). Objective: Multicenter, randomized, open-l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0d8060cbccaf2749d1072a2445417a6
https://pubmed.ncbi.nlm.nih.gov/32580188

Zobrazit plný text záznamu

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

Autor: Michael Reusch, Tetsuro Otsuka, Toshihiro Misumi, Manabu Iwasaki, Tadao Akizawa

Publikováno v: Advances in Therapy

Introduction This study evaluated efficacy and safety/tolerability of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis-dependent chronic kidney disease (NDD-CKD) patients. Methods In this phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad285faddd0a6a8ca789c63ff88de929
https://pubmed.ncbi.nlm.nih.gov/30953333

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání